The SLC30A10 gene encodes a manganese (Mn) efflux transporter that plays a critical role in maintaining manganese homeostasis in the body. This transporter is essential for protecting cells from manganese toxicity, particularly in the brain where manganese accumulation leads to severe neurological deficits. Loss-of-function mutations in SLC30A10 cause hereditary manganese-induced neurotoxicity, characterized by hypermanganesaemia, early-onset dystonia, paraparesis, and late-onset parkinsonism. This gene represents a crucial link between metal homeostasis and neurodegenerative processes.
| Property | Value |
|---|---|
| Gene Symbol | SLC30A10 |
| Protein | Manganese efflux transporter |
| Synonyms | ZnT10, ZNT10 |
| Chromosomal Location | 1q41 (human) |
| NCBI Gene ID | 201931 |
| UniProt ID | Q6NXR1 |
| Gene Family | SLC30 (ZnT) family |
| Protein Length | 486 amino acids |
| Molecular Weight | ~52 kDa |
SLC30A10 belongs to the ZnT (SLC30) family of metal cation transporters, which typically function as zinc efflux transporters. However, SLC30A10 has evolved to specifically transport manganese, representing a unique specialization within this family. The gene is located on chromosome 1q41 in humans and consists of multiple exons encoding a polytopic membrane protein.
The SLC30A10 protein is a predicted transmembrane protein with six to eight membrane-spanning domains. Like other ZnT family members, it contains the characteristic transporter architecture that facilitates metal ion export from the cytosol. The protein localizes to the plasma membrane where it functions as an efflux pump, exporting manganese ions from cells.
Key structural features:
SLC30A10 functions as a Mn²⁺/H⁺ antiporter:
SLC30A10 protein architecture:
| Feature | Details |
|---|---|
| Transmembrane domains | 6 α-helices |
| N-terminus | Intracellular |
| C-terminus | Intracellular |
| Metal binding | Histidine-rich loop |
| Dimerization | Functional dimer required |
Manganese is an essential trace metal required for proper functioning of numerous enzymes, including mitochondrial superoxide dismutase (MnSOD) and glutamine synthetase. However, excess manganese is highly neurotoxic, leading to manganism—a Parkinson's-like syndrome with distinct clinical features.
SLC30A10 is the primary mechanism for cellular manganese export. By effluxing manganese from cells, particularly in the liver and brain, this transporter prevents toxic accumulation. The liver plays a major role in systemic manganese clearance, and SLC30A10 expression in hepatocytes is crucial for preventing serum manganese elevation.
Mechanism of Mn efflux:
Intracellular Mn²⁺ → SLC30A10 → Extracellular/Excretory pathwa
↓
Proton gradient coupling
↓
Energy-dependent export
SLC30A10 exhibits a distinctive expression pattern:
The basal ganglia, particularly the striatum and substantia nigra, are highly susceptible to manganese toxicity. SLC30A10 expression in these regions provides protection against manganese-induced neurodegeneration. Research by Chen et al. (2021) demonstrated that the transporter protects against deficits in motor function and dopaminergic neurotransmission under physiological conditions.
SLC30A10 transports manganese as Mn²⁺, using proton gradient coupling for energy. The transporter exports manganese against concentration gradients, preventing intracellular accumulation. This function is particularly important in:
SLC30A10 functions in concert with the divalent metal transporter 1 (DMT1/SLC11A2), which mediates manganese uptake. The balance between DMT1-mediated import and SLC30A10-mediated export determines cellular manganese levels. Disruption of either transporter can lead to manganese dysregulation.
SLC30A10 expression is regulated at multiple levels:
Recessive loss-of-function mutations in SLC30A10 cause a rare hereditary disorder characterized by:
This condition represents a unique example of a monogenic disorder directly causing manganese-related neurodegeneration. Patients present with a combination of motor symptoms that distinguish manganism from idiopathic Parkinson's disease.
While SLC30A10 mutations cause a distinct clinical syndrome, the gene's role in manganese homeostasis has generated interest in its potential involvement in sporadic Parkinson's disease. Manganese exposure has been associated with increased Parkinson's risk in occupational settings, and genetic variants in SLC30A10 might modify individual susceptibility to manganese-induced neurotoxicity.
Research by Martinez et al. (2020) explored the relationship between SLC30A10 variants and Parkinson's disease susceptibility, though definitive conclusions remain elusive.
Given manganese's role in oxidative stress and neuroinflammation, SLC30A10 dysfunction may contribute to other neurodegenerative conditions where metal homeostasis is disrupted, including:
Excess manganese exerts toxic effects through multiple mechanisms:
Oxidative stress:
Neuroinflammation:
Excitotoxicity:
The basal ganglia are particularly susceptible to manganese:
Substantia nigra pars reticulata (SNr):
Globus pallidus (GP):
Striatum:
For patients with SLC30A10 deficiency, chelation therapy using EDTA or other manganese-chelating agents can reduce body manganese burden and improve neurological symptoms. Early intervention is crucial to prevent irreversible basal ganglia damage.
Chelation approaches:
SLC30A10 represents a potential gene therapy target for manganese-related disorders. Viral vector delivery of functional SLC30A10 to the liver or brain could restore manganese homeostasis in affected individuals.
Gene therapy strategies:
Understanding SLC30A10 function has broader implications for developing neuroprotective strategies targeting metal homeostasis in neurodegenerative diseases. Modulators of SLC30A10 activity could potentially be developed to enhance cellular protection against manganese toxicity.
Diagnosing SLC30A10-related disorder:
| Test | Finding | Significance |
|---|---|---|
| Blood Mn | Elevated | Increased total Mn |
| MRI T1 | Hyperintensity | Basal ganglia Mn deposition |
| Genetic testing | Biallelic mutations | Confirm diagnosis |
| Liver function | Variable | Hepatic involvement |
Current management strategies:
Outcomes with early intervention:
SLC30A10 shows varying conservation across species: